The non-invasive device, already available in Canada, Australia, and New Zealand, delivers low-level microcurrent through closed eyelids in 32-minute in-clinic sessions.
The agreement brings J&J a next-generation bispecific antibody that outpaced faricimab on early anatomic measures in the phase 1b JADE trial, with Blackstone Life Sciences committing $750 million to fund phase 3 development.